Emmaus Life Sciences, Inc. (EMMA)

USD 0.01

(0.0%)

Market Cap (In USD)

510.92 Thousand

Revenue (In USD)

29.59 Million

Net Income (In USD)

-3.73 Million

Avg. Volume

40.31 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-4-0.13215
PE
-
EPS
-
Beta Value
6.605
ISIN
US29137T1016
CUSIP
29137T101
CIK
822370
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Willis C. Lee M.S.
Employee Count
-
Website
https://www.emmausmedical.com
Ipo Date
2000-05-09
Details
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

More Stocks